Advanced Filters
noise

Discoid Lupus Erythematosus Clinical Trials

A listing of Discoid Lupus Erythematosus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 286 clinical trials
E Ebtehal Alaa El-Din Kotop Mohamed, Lecturer

" TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by diverse clinical manifestations, prominently involving the skin.

18 - 60 years of age All Phase N/A

Systemic Lupus Erythematosus Within the Framework of the Multidisciplinary Consultation

Diagnosis and follow up of a lupus cohort in a multidisciplinary consultation in Brest ( France)

18 - 80 years of age All Phase N/A
Z Zhanguo Li, Doctor

A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus

This study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.

18 - 80 years of age All Phase 3
H Hongyan Tong

Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the refractory systemic lupus erythematosus.

18 - 65 years of age All Phase N/A
I Ioannis Parodis, MD PhD | Associate Professor

Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus Nephritis

Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE). Among people living with SLE, 35-60% will develop LN during the course of the disease. This complication is one of the factors that contribute to deterioration of the renal function. Some centres perform kidney biopsies …

18 years of age All Phase N/A
H He Huang, Doctor

CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis.

18 years of age All Phase 0
S Sanbin Wang, MD

JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)

Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of active systemic lupus erythematosus (SLE)

14 - 75 years of age All Phase 1/2
J Jinxia Zhao

IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)

The study is a single-arm, open-label clinical trial intended to recruit 6 refractory SLE subjects who meet the inclusion and exclusion criteria. The subjects will receive IM19 CAR-T cell infusion therapy at a dose of 1×10\^6/kg or 1×10\^8 CAR-T cells . The primary endpoint is to evaluate the improvement in …

18 - 65 years of age All Phase N/A

Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus

This study is a single-center, open-label, single-arm trial. The aim of this study is to investigate the safety and efficacy of anti-CD19 CAR-NK cells in patients with refractory/relapsed systemic lupus erythematosus.

18 - 65 years of age All Phase 1
M Mengtao Li, Doctor

Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by heterogeneous clinical manifestations ranging from mild cutaneous involvement to severe multi-organ damage. While its pathogenesis involves complex cytokine dysregulation, emerging evidence implicates IL-17 as a potential contributor. Elevated serum IL-17 levels have been observed in SLE patients compared to …

18 - 65 years of age All Phase 1

Simplify language using AI